Top cited articles

The quality and impact of our journals are dependent on many different measures. We’ve provided here some of those metrics for Annals of the Rheumatic Diseases, to reflect the latest 2019 data, that remain important to our authors. We’ve also listed our top most cited articles from each of the last two years, free to read.


To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
FEB 2019 10.1136/annrheumdis-2018-213474

Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study
FEB 2019 10.1136/annrheumdis-2017-212763

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
JUN 2019 10.1136/annrheumdis-2019-215089

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
FEB 2019 10.1136/annrheumdis-2018-214229

2018 update of the EULAR recommendations for the management of hand osteoarthritis
JAN 2019 10.1136/annrheumdis-2018-213826

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts
JAN 2019 10.1136/annrheumdis-2018-213708

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal
JUL 2019 10.1136/annrheumdis-2018-214856

EULAR recommendations for the management of antiphospholipid syndrome in adults
OCT 2019 10.1136/annrheumdis-2019-215213

Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
APR 2019 10.1136/annrheumdis-2018-214273

Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial
MAR 2019 10.1136/annrheumdis-2018-214245


Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
JAN 2018 10.1136/annrheumdis-2017-211734

TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort
JAN 2018 10.1136/annrheumdis-2017-211544

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?
FEB 2018 10.1136/annrheumdis-2017-211555

EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice
MAY 2018 10.1136/annrheumdis-2017-212649

Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
FEB 2018 10.1136/annrheumdis-2017-211937

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
APR 2018 10.1136/annrheumdis-2017-212127

Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study
FEB 2018 10.1136/annrheumdis-2017-212196

Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)
FEB 2018 10.1136/annrheumdis-2017-211682

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)
MAR 2018 10.1136/annrheumdis-2017-211878

A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease
MAY 2018 10.1136/annrheumdis-2017-212403

Journal Metrics:

Days to first decision: 10
Days from acceptance to publication: 13

2 year Impact Factor (JCR): 16.102
SciMago Journal Rank (SJR): 6.142
Eigenfactor: 0.07293
Citescore: 25.9

2019 total content accesses: 2,500,000
Total Altmetric Mentions: 8412